Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)-Reference-Cited by-同舟云学术

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Published:2009-03 Issue:3 Volume:26 Page:268-278
ISSN:0742-3071
Container-title:Diabetic Medicine
language:en
Short-container-title:

Author:

Marre M.,Shaw J.,Brändle M.,Bebakar W. M. W.,Kamaruddin N. A.,Strand J.,Zdravkovic M.,Le Thi T. D.,Colagiuri S.,

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1464-5491.2009.02666.x/fullpdf

Reference22 articles.

1. The physiology of glucagon-like peptide 1;Holst;Physiol Rev,2007

2. Management of hyperglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes;Nathan;Diabetes Care,2006

3. Update on Type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm;Green;Int J Clin Pract,2007

4. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in Type 2 diabetes;Drucker;Lancet,2006

5. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration;Knudsen;J Med Chem,2000

Cited by 690 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tirzepatide: unveiling a new dawn in dual-targeted diabetes and obesity management;Expert Review of Endocrinology & Metabolism;2024-08-28

2. Use of continuous glucose monitoring when initiating glucagon‐like peptide‐1 receptor agonist therapy in insulin‐treated diabetes;Diabetes, Obesity and Metabolism;2024-08-28

3. Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus;Pharmacia;2024-08-02

4. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists;Frontiers in Endocrinology;2024-07-24

5. Liraglutide innovations: a comprehensive review of patents (2014–2024);Pharmaceutical Patent Analyst;2024-07-16